PRIMARY SCLEROSING CHOLANGITIS (PSC) AND TAMOXIFEN

There is no effective medical treatment for primary sclerosing cholang itis (PSC). Tamoxifen was found to have anti-fibrotic properties and h as only few and rare side-effects. We gave 6 PSC patients 20 mg/day of tamoxifen and we studied its influence on the alkaline phosphatase (A LP) serum levels, Duration of treatment was from 1 to 8 months. Two pa tients showed a decline of their ALP to normal values, the other 4 pat ients showed improvement. Our results are encouraging and a larger sca le study for a longer period of time is needed to evaluate the effect of tamoxifen on PSC patients, In such a study, liver biopsies should b e performed for histological evaluation.